Results 31 to 40 of about 4,644,977 (251)
Long-term results of anti-VEGF therapy in macular edema caused by central retinal vein occlusion
Российский офтальмологический журнал, 2023 Purpose. To evaluate long-term results of anti-VEGF therapy performed in a modified “treat-and-extend” regimen in macular edema secondary to central retinal vein occlusion.Material and methods.
A. B. Galimova, V. U. Galimova
doaj +1 more source
, 2021 One approach to anticancer treatment is targeted anti-angiogenic therapy (AAT) based on prevention of blood vessel formation around the developing cancer cells.
Katarzyna Masłowska +9 more
core +1 more source
Biomarkers as Predictive Factors of Anti-VEGF Response [PDF]
, 2022 Age-related macular degeneration is the main cause of irreversible vision in developed countries, and intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are the current gold standard treatment today.
Bobadilla, Miriam +14 more
core +1 more source
Mechanistic insights into the heterogeneous response to anti‐VEGF treatment in tumors
Computational and Systems Oncology, 2021 Vascular endothelial growth factor (VEGF) is a strong promoter of angiogenesis in tumors, and anti‐VEGF treatment, such as a humanized antibody to VEGF, is clinically used as a monotherapy or in combination with chemotherapy to treat cancer patients ...
Ding Li, Stacey D. Finley
doaj +1 more source
, 2021 Anti-angiogenic Therapy for Lung Cancer: Focus on Bioassay Development in a Quest for Anti-VEGF ...
Urvashi Bhati (13795252) +5 more
core
Anti-VEGF-A antibody does not recognize VEGF-A : Incubation with VEGF-A antibody
, 2011 This antibody recognizes the VEGF-A monomer (22.5 kDa) and dimer (45 kDa) in control and glaucomatous retinas (first two lanes). VEGF-A antibody does not recognize 25 ng, 100 ng, or 250 ng of VEGF-A recombinant protein in the same membrane (last three ...
Wei Huang (36889) +5 more
core +1 more source
VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. [PDF]
, 2016 The inadequate transport of drugs into the tumor tissue caused by its abnormal vasculature is a major obstacle to the treatment of cancer. Anti-vascular endothelial growth factor (anti-VEGF) drugs can cause phenotypic alteration and maturation of the ...
Tenspolde, M +31 more
core +2 more sources
Indian Journal of Ophthalmology, 2023 Intravitreal injection of anti- Vascular Endothelial Growth Factor (VEGF)is commonly used to treat patients with diabetic macular edema (DME). However, the injection alone requires high cost and compliance.
Parangeni M Lubis +2 more
doaj +1 more source
Visual Outcome after Intravitreal Anti-VEGF Therapy for Macular Neovascularisation Secondary to Sorsby's Fundus Dystrophy: A Systematic Review. [PDF]
, 2021 The aim of this paper is to summarise our own and to review published experience regarding the long-term outcome of intravitreal treatment for macular neovascularisation (MNV) secondary to Sorsby's fundus dystrophy (SFD).
Baston, Arthur +7 more
core +2 more sources
Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment
Molecular Oncology, EarlyView.This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley +1 more source